These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 26270186)

  • 1. Prognostic Significance of Cutaneous Adverse Events Associated With Pembrolizumab Therapy.
    Lo JA; Fisher DE; Flaherty KT
    JAMA Oncol; 2015 Dec; 1(9):1340-1. PubMed ID: 26270186
    [No Abstract]   [Full Text] [Related]  

  • 2. Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression.
    Sanlorenzo M; Vujic I; Daud A; Algazi A; Gubens M; Luna SA; Lin K; Quaglino P; Rappersberger K; Ortiz-Urda S
    JAMA Dermatol; 2015 Nov; 151(11):1206-1212. PubMed ID: 26222619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Will cetuximab-induced follicular rash get worse with moisturizers containing liquid paraffinum?
    Manganoni AM; Pavoni L; Calzavara-Pinton P
    Jpn J Clin Oncol; 2014 Jun; 44(6):607-8. PubMed ID: 24755543
    [No Abstract]   [Full Text] [Related]  

  • 4. [Skin toxicity of monoclonal antibodies].
    Cignola S; Campagna S; Gonella S
    Assist Inferm Ric; 2017; 36(4):214-221. PubMed ID: 29200214
    [No Abstract]   [Full Text] [Related]  

  • 5. [Generalized pruritic eruption during terbinafine treatment].
    Amouri M; El Euch D; El Ouni B; Daoued O; Ouselati MH; Ferjani M; Dhahri AB
    Presse Med; 2008 Dec; 37(12):1836-40. PubMed ID: 18656325
    [No Abstract]   [Full Text] [Related]  

  • 6. Spironolactone-associated cutaneous effects: a case report and a review of the literature.
    Gupta AK; Knowles SR; Shear NH
    Dermatology; 1994; 189(4):402-5. PubMed ID: 7873830
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Gottron-like papules induced by sunitinib].
    Martorell-Calatayud A; Sanmartín O; Traves-Zapata V; Guillén C
    Actas Dermosifiliogr; 2011 Jun; 102(5):385-7. PubMed ID: 21481331
    [No Abstract]   [Full Text] [Related]  

  • 8. Cutaneous hemophagocytosis after alemtuzumab injection in a patient with Sézary syndrome.
    Jawed SI; Busam K; Wang X; Horwitz S; Querfeld C
    JAMA Dermatol; 2014 Sep; 150(9):1021-3. PubMed ID: 25029560
    [No Abstract]   [Full Text] [Related]  

  • 9. Cutaneous adverse events of epidermal growth factor receptor inhibitors: A retrospective review of 99 cases.
    Chanprapaph K; Pongcharoen P; Vachiramon V
    Indian J Dermatol Venereol Leprol; 2015; 81(5):547. PubMed ID: 25994883
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Skin toxicities of targeted therapies.
    Segaert S; Chiritescu G; Lemmens L; Dumon K; Van Cutsem E; Tejpar S
    Eur J Cancer; 2009 Sep; 45 Suppl 1():295-308. PubMed ID: 19775626
    [No Abstract]   [Full Text] [Related]  

  • 11. Injection site reaction to adalimumab: Positive skin test and successful rapid desensitisation.
    Bavbek S; Ataman Ş; Bankova L; Castells M
    Allergol Immunopathol (Madr); 2013; 41(3):204-6. PubMed ID: 23063342
    [No Abstract]   [Full Text] [Related]  

  • 12. [Management of the cutaneous side effects of chemotherapies and targeted therapies].
    Delyon J; Gerard M; Nicodeme M; Fromantin I; Loirat D
    Soins; 2015 Jun; (796):17-24. PubMed ID: 26146316
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of cumulative toxicity after complete melanoma response with pembrolizumab.
    Hsieh AH; Faithfull S; Brown MP
    BMJ Case Rep; 2017 Feb; 2017():. PubMed ID: 28148549
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Desensitization to chemotherapeutic agents.
    Lieberman P; Castells M
    J Allergy Clin Immunol Pract; 2014; 2(1):116-7. PubMed ID: 24565784
    [No Abstract]   [Full Text] [Related]  

  • 15. Is cetuximab-induced rash conclusion really a remnant of the skin erythema dose?
    Oskan F; Belka C; Manapov F
    Int J Radiat Oncol Biol Phys; 2013 Nov; 87(3):462-3. PubMed ID: 24074919
    [No Abstract]   [Full Text] [Related]  

  • 16. EGFR-targeted therapy and related skin toxicity.
    Morse L; Calarese P
    Semin Oncol Nurs; 2006 Aug; 22(3):152-62. PubMed ID: 16893744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ado-trastuzumab emtansine (Kadcyla) for HER2-positive metastatic breast cancer.
    Med Lett Drugs Ther; 2013 Sep; 55(1425):75-6. PubMed ID: 24662957
    [No Abstract]   [Full Text] [Related]  

  • 18. Plaque Psoriasis Flare and Peripheral Edema in a Patient Treated With Atezolizumab.
    Santos-Juanes J; Munguía Calzada P; Álvarez Fernández C
    Actas Dermosifiliogr (Engl Ed); 2019 Jun; 110(5):410-411. PubMed ID: 30366590
    [No Abstract]   [Full Text] [Related]  

  • 19. Psoriasis-like Eruption triggered by Dupilumab Therapy.
    Russo F; Provvidenziale L; Bruzziches F; Fiorani D; Santi F; Lamberti A; Lazzeri L; Flori ML; Rubegni P
    Dermatitis; 2021 Nov-Dec 01; 32(6):e147-e148. PubMed ID: 34310097
    [No Abstract]   [Full Text] [Related]  

  • 20. Eruptive Keratoacanthomas Associated With Pembrolizumab Therapy.
    Freites-Martinez A; Kwong BY; Rieger KE; Coit DG; Colevas AD; Lacouture ME
    JAMA Dermatol; 2017 Jul; 153(7):694-697. PubMed ID: 28467522
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.